INHALE first to use Oxford Nanopore MinION sequencing

The INHALE project will be the first in the world to use Oxford Nanopore MinION sequencing in a clinical trial setting for diagnosis of HAP/VAP.

27 July 2017

MinION can sequence genomes in anything within two minutes to two days depending on their size and complexity, supplying doctors with a genetic read-out that can help them pick effective treatments more quickly.

The trial is funded by public body the National Institute for Health Research (NIHR) and is designed to enable the most effective diagnostic tool to get fast-track approval for use in the NHS in around five to ten years’ time.

Highlights in Medical Sciences

Groundbreaking bowel cancer trial follow-up shows zero relapses

Research

Groundbreaking bowel cancer trial follow-up shows zero relapses

Patients with a specific bowel cancer who were given short-course immunotherapy before surgery, instead of post-op chemotherapy, remained cancer-free after nearly three years of follow-up.

Drug to treat aggressive leukaemia approved for use in adults

Research

Drug to treat aggressive leukaemia approved for use in adults

Adult patients with aggressive leukaemia will soon be able to receive a breakthrough immunotherapy, developed by UCL researchers, on the NHS after approval by NICE.

Millions could benefit from faster prostate cancer scan

Research

Millions could benefit from faster prostate cancer scan

Results of the PRIME trial involving UCL Medical Sciences researchers have found that a quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan.

INHALE first to use Oxford Nanopore MinION sequencing

Links

Highlights in Medical Sciences

Groundbreaking bowel cancer trial follow-up shows zero relapses

Drug to treat aggressive leukaemia approved for use in adults

Millions could benefit from faster prostate cancer scan